Duquesne University and Flag Therapeutics Inc. of Raleigh, N.C., have agreed to a worldwide licensing agreement for two classes of water-soluble cancer drugs.
According to a statement, the two small-molecule compounds will be the first to combine the dual action of two major classes of cancer drugs into a single molecule.
One class of drugs circumvents naturally-occurring mechanisms of drug resistance while the other works to interrupt cell multiplication. By combining the two, the cancer cells will be targeted when they are most vulnerable while avoiding harm to healthy cells.
Heading the project at Duquesne is cancer researcher Aleem Gangiee.
Steve Twedt: email@example.com or 412-263-1963.